Atom | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Funder: National Institutes of Health

Due Dates: April 4, 2025 (Full application) | May 4, 2025 (Letter of Intent) | October 3, 2025 (Full application) | September 3, 2025 (Letter of Intent)

Funding Amounts: Up to $300,000 direct costs per year, for up to 3 years (R33 mechanism); ~2 awards anticipated

Summary: Supports advanced development and validation of innovative biospecimen science technologies to improve sample quality and handling for basic and clinical cancer research.

Key Information: Clinical trials are not allowed; applications must include quantitative performance measures; annual PI meeting attendance required.

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Sign in to see full grant listing